Clinical Trials on Refractory Tumor

Total 19266 results

AstraZeneca

Completed

An Open-Label, Dose-Escalation Study of AZD2461

Refractory Solid Tumors | Cancer Tumor

United States
National Cancer Institute (NCI)

Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid Tumor

United States
Immatics US, Inc.

Completed

TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (ACTengine)

Cancer | Solid Tumor | Refractory Solid Tumors | Recurrent Solid Tumors

United States, Germany
Baodong Qin

Recruiting

Efficacy and Safety of Precision Therapy in Refractory Tumor

Refractory Tumor | Rare Tumor

China
St. Jude Children's Research Hospital
Pfizer; Ipsen

Recruiting

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Peripheral Primitive Neuroectodermal Tumor | Recurrent Rhabdoid Tumor | Recurrent... and other conditions

United States, Canada
Eli Lilly and Company
Children's Oncology Group

Completed

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Recurrent Tumor | Pediatric Solid Tumor | Refractory Tumor | CNS Malignancies

United States
National Health Research Institutes, Taiwan
National Cheng-Kung University Hospital

Recruiting

Neoantigen Derived DCs as Cancer Treatment

Solid Tumor | Refractory Tumor

Taiwan
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
Sorrento Therapeutics, Inc.

Withdrawn

Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

Solid Tumor | Relapsed Solid Tumor | Refractory Tumor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Recruiting

A Study of DCR-STAT3 in Adults With Solid Tumors

Solid Tumor, Adult | Refractory Tumor

United States
National University Hospital, Singapore
Otsuka Pharmaceutical Co., Ltd.

Unknown

Phase IIa Dose-Expansion and Biomarker Study of OPB-111077

NPC | Refractory Tumor

Singapore
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors

Tumors | Incurable Platinum Refractory Germ Cell Tumors

United States
Sidnei Epelman

Unknown

Oxaliplatin for Children With Solid Tumors

Relapsed Solid Tumor | Refractory Solid Tumor

Brazil
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
SupremeCure Pharma Inc.

Withdrawn

Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors

Refractory Solid Tumor
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Sorrento Therapeutics, Inc.

Recruiting

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Solid Tumor | Refractory Tumor | Relapsed Solid Neoplasm

United States
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression

Refractory Solid Tumor

China
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors

Refractory Solid Tumor

China
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico, Australia
M.D. Anderson Cancer Center

Recruiting

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Refractory Neuroblastoma | Refractory Rhabdomyosarcoma | Desmoplastic Small Round Cell Tumor | Recurrent Malignant Peripheral Nerve Sheath Tumor | Ewing Sarcoma/Peripheral... and other conditions

United States
Sairopa B.V.

Recruiting

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Metastatic Solid Tumor | Solid Tumor, Adult | Refractory Cancer

United States, Moldova, Republic of
Samsung Medical Center
Ministry of Health, Republic of Korea

Not yet recruiting

Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid Tumor

Korea, Republic of
Eli Lilly and Company

Completed

Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

Cancer | Refractory Solid Tumor

United States
National Cancer Institute (NCI)

Active, not recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia
Gustave Roussy, Cancer Campus, Grand Paris
Innovative Therapies For Children with Cancer Consortium

Unknown

Proof -of -Concept Study To Stratify Targeted Therapies Adapted To Molecular Profiling (MAPPYACTS)

Relapsed or Refractory Pediatric Tumor

France, Ireland, Israel, Italy, Spain
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent... and other conditions

United States, Puerto Rico
Livzon Pharmaceutical Group Inc.
Palm Beach CRO; Keystone Bioanalytical, Inc.

Completed

Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

Solid Tumor Refractory to Standard Therapy

United States
Taiga Biotechnologies, Inc.

Recruiting

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Cancer | Refractory Cancer | Tumor, Solid

Israel, United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents

Malignant Tumors | Refractory Tumors

France
Antisoma Research

Completed

Phase I Safety Study of DMXAA in Refractory Tumors (DART)

Refractory Tumors
National Cancer Institute (NCI)

Recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Malignant Solid Neoplasm | Rhabdoid Tumor | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Rhabdoid Tumor | Refractory Rhabdoid Tumor | Epithelioid Sarcoma | Kidney Medullary Carcinoma | Atypical Teratoid/Rhabdoid Tumor | Poorly Differentiated Chordoma | Recurrent Atypical... and other conditions

United States, Canada, Australia
National Cancer Institute (NCI)
Children's Oncology Group

Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico
Indiana University School of Medicine
AstraZeneca

Terminated

A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR (IUCRO-0021)

Refractory Germ Cell Tumors Expressing EGRF

United States
Radboud University Medical Center
Bayer

Completed

Phase 1 Study With Sorafenib and Sirolimus

Advanced Solid Tumor | Refractory to Standard Therapies

Netherlands
HotSpot Therapeutics, Inc

Recruiting

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Solid Tumor, Adult | Relapsed Cancer | Refractory Cancer

United States
Samsung Medical Center

Completed

Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
Samsung Medical Center

Completed

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
Samsung Medical Center

Completed

Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Refractory Solid Tumors | Relapsed Solid Tumors

China
Regeneron Pharmaceuticals
Pacific Pediatric Neuro-Oncology Consortium

Terminated

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

High Grade Glioma | Diffuse Intrinsic Pontine Glioma | Relapsed Solid Tumor | Refractory Solid Tumor | Relapsed Central Nervous System Tumor | Refractory Central Nervous System Tumor

United States
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Relapsed Solid Tumor | Refractory Solid Tumor

United States, Canada, France, Australia, Belgium, Germany, Spain, Italy
Emory University

Completed

Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors (AflacST1501)

Diffuse Intrinsic Pontine Glioma | Brain Tumor, Recurrent | Solid Tumor, Recurrent | Neuroblastoma, Recurrent, Refractory | Ewing Sarcoma, Recurrent, Refractory | Rhabdomyosarcoma, Recurrent, Refractory | Osteosarcoma, Recurrent, Refractory | Rhabdoid Tumor, Recurrent, Refractory

United States
Ruijin Hospital

Recruiting

Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

Refractory Solid Tumors

China
Samsung Medical Center

Completed

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
SCRI Development Innovations, LLC
Bayer

Completed

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Refractory Solid Tumors

United States
Vertex Pharmaceuticals Incorporated
National Cancer Institute (NCI)

Withdrawn

A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors

Refractory Solid Tumors

United States
University of Colorado, Denver
University of Kentucky

Completed

A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

Refractory Solid Tumors | Relapsed Solid Tumors

United States

Clinical Trials on Refractory Tumor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations